	US 11,865,107 B2
	Pharmaceutical composition
Gary Kompothecras, Sarasota, FL (US); Michael Mullan, Sarasota, FL (US); and Daniel Paris, Sarasota, FL (US)
Filed by Asclepius Pharmaceutical, LLC, Sarasota, FL (US)
Filed on Sep. 2, 2020, as Appl. No. 17/009,960.
Application 17/009,960 is a continuation in part of application No. 16/602,690, filed on Nov. 20, 2019, abandoned.
Claims priority of provisional application 62/917,129, filed on Nov. 21, 2018.
Prior Publication US 2021/0052559 A1, Feb. 25, 2021
Int. Cl. A61K 31/4375 (2006.01); A61K 9/48 (2006.01); A61K 47/46 (2006.01); A61K 47/36 (2006.01); A61K 31/4355 (2006.01); A61K 9/00 (2006.01); A61K 36/9066 (2006.01); A61K 36/21 (2006.01); A61K 36/54 (2006.01); A61K 47/22 (2006.01)

CPC A61K 31/4375 (2013.01) [A61K 9/0014 (2013.01); A61K 9/48 (2013.01); A61K 31/4355 (2013.01); A61K 36/21 (2013.01); A61K 36/54 (2013.01); A61K 36/9066 (2013.01); A61K 47/22 (2013.01); A61K 47/36 (2013.01); A61K 47/46 (2013.01)]

15 Claims

1. A composition comprising a therapeutically effective amount of at least

a. one alkaloid selected from the group consisting essentially of berberine, allocryptopine, alpha-homochelidonine, beta-homochelidonine, chelidonine, chelerythrine, coptisine, magnoflorine, protopine, sparteine, chelamine, and sanguinaria,

b. at least 50 mg of beetroot,

c. and at least one component selected from the group consisting essentially of allocryptopine, chelamine, chelidonine, chelerythrine, coptisine, magnoflorine, protopine, sparteine, alpha-homochelidonine, beta-homochelidonine, chelidonic acid, malic acid, and citric acid, wherein the composition is configured to be administered to a subject known to have arthritis.